Why Narrative Matters

America’s opioid crisis has long been framed as a morality play. In the standard telling, pharmaceutical companies pushed dangerous drugs, physicians prescribed too freely, and patients became addicted. That story contains truth, but it is no longer enough. And because it is incomplete, it is no longer helpful for solving the problem.

The Centers for Disease Control and Prevention (CDC) still describes the epidemic in “three waves”: prescription opioids in the 1990s, heroin beginning around 2010, and synthetic opioids, especially illicitly manufactured fentanyl, beginning in 2013. That framework helped organize a chaotic public-health emergency. It also narrowed the public-health focus, encouraging the belief that if we controlled prescribing aggressively enough, the crisis itself would recede.

But the crisis kept changing while the narrative stood still.

Prescription opioid dispensing has fallen steadily for years. The CDC reports that the national dispensing rate declined from 46.8 prescriptions per 100 people in 2019 to 35.4 in 2024. Meanwhile, in 2023, about 69% of all overdose deaths involved synthetic opioids, primarily illicit fentanyl and fentanyl analogs, and the prescription-opioid death rate fell while synthetic-opioid deaths remained vastly higher. In other words, the country spent years fighting yesterday’s epidemic while a more lethal, illicit market surged into the gap.

This is why narrative matters. Stories do not merely describe crises; they organize public sympathy, political urgency, and policy response. Once a simplified story hardens into conventional wisdom, it becomes difficult to correct, even when the evidence changes. That has consequences. Patients with legitimate pain can become collateral damage. Public attention can remain fixed on prescription volume while illicit fentanyl, counterfeit pills, and polysubstance use reshape overdose risk in real time. And policymakers can congratulate themselves for tightening one spigot while the floodwaters rise elsewhere.

A better narrative would begin with a harder truth: this crisis was never only about supply. It was also about demand—about pain, trauma, despair, dislocation, and the environments in which drug use becomes more likely and recovery more difficult. The data consistently show that opioid mortality is shaped by more than biological exposure to a molecule; it is governed by the environment in which that exposure occurs. In one widely cited study, counties that experienced automotive assembly plant closures saw opioid overdose mortality rise sharply; five years after a closure, overdose mortality was 85% higher than expected compared with similar unexposed counties. Factories do not prescribe fentanyl. But economic collapse can hollow out the structures that make life bearable: work, identity, routine, hope, and social cohesion.

That wider lens also reveals how badly our public story has obscured inequity. In 2023, the overdose death rate remained highest among American Indian and Alaska Native people, while Black Americans saw overdose death rates rise even as White rates declined. Earlier CDC analyses found that from 2019 to 2020, overdose death rates rose 44% among Black people and 39% among American Indian and Alaska Native people, with especially severe burdens in places marked by high income inequality. Yet the public imagination has often clung to an older image of the crisis as overwhelmingly white, rural, and prescription-driven. That framing has not merely been incomplete. It has distorted attention, research priorities, and resource allocation.

None of this means pharmaceutical misconduct should be excused. It should not. Nor does it mean careless prescribing was harmless. It was not. But a mature public-health response must be capable of holding more than one truth at a time. While reckless marketing and weak regulation played their parts, so did deindustrialization, untreated mental illness, unstable housing, racial inequity, social isolation, and a treatment system that remains fragmented and inaccessible to many who need it most.

We should be wary of any explanation that is emotionally satisfying precisely because it is simple. The opioid crisis is not one story. It is many overlapping stories: of pain and addiction, of licit and illicit supply, of policy failure and economic abandonment, of stigma and racial inequity, of trauma carried across lifetimes, and of communities left to absorb the consequences.

If we keep telling the wrong story, we will keep designing the wrong response.

America does not need another round of moral certainty. It needs intellectual humility. It needs a public narrative wide enough to accommodate changing evidence, structural causes, and unequal burdens. And it needs policymakers willing to admit that the crisis cannot be solved simply by punishing one class of actors or restricting one class of drugs while leaving the underlying architecture of despair untouched.

The story we tell about the opioid crisis is not a side issue. It is part of the crisis itself.

Lynn R. Webster M.D. is Senior Fellow Center for U.S. Policy and is co-author of the forthcoming book, Deconstructing Toxic Narratives—Data, Disparities, and a New Path Forward in the Opioid Crisis, to be published by Springer Nature.